The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of FOLFOXIRI plus panitumumab (pmab) followed by evaluation for resection, in patients (pts) with metastatic KRAS wild-type colorectal cancer (mCRC) with liver metastases only.
Ahmed Zakari
No relevant relationships to disclose
Victor G. Gian
No relevant relationships to disclose
Anthony Alan Meluch
No relevant relationships to disclose
James D. Peyton
No relevant relationships to disclose
David Michael Waterhouse
No relevant relationships to disclose
Andrew J. Lipman
No relevant relationships to disclose
Ralph V. Boccia
No relevant relationships to disclose
Suzanne Fields Jones
No relevant relationships to disclose
Johanna C. Bendell
No relevant relationships to disclose